Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

T1 Lung Cancers: Sensitivity of Diagnosis with Fluorodeoxyglucose PET1

T1 Lung Cancers: Sensitivity of Diagnosis with Fluorodeoxyglucose PET1 PURPOSE: To determine the sensitivity of fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with T1 (≤3 cm) lung cancers. MATERIALS AND METHODS: One hundred eighty-five patients with 192 histopathologically proved T1 lung cancers underwent FDG PET imaging at the time of diagnosis. PET results were correlated with tumor size, histopathologic findings, and patient outcome by using the two-sample t test, exact χ 2 test, and log rank test, respectively. RESULTS: Of the 192 lesions, 183 (95%) that ranged in size from 0.5 to 3.0 cm in diameter (mean, 2.0 cm) were positive at PET (ie, demonstrated increased FDG uptake). Of the 192 lesions, nine (5%) that ranged in size from 0.3 to 2.5 cm in diameter (mean, 1.3 cm) were negative at PET (ie, demonstrated low FDG uptake). Patients with small tumors, as well as those with carcinoid tumors and bronchioloalveolar cell carcinoma, were more likely to have a negative PET scan ( P = .004, P = .003, respectively). In addition, patients with a negative PET scan who subsequently proved to have cancer had significantly longer survival than did patients with a positive scan and cancer ( P = .043). CONCLUSION: Most T1 lung cancers show increased FDG uptake on PET scans. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Radiology Radiological Society of North America, Inc.

T1 Lung Cancers: Sensitivity of Diagnosis with Fluorodeoxyglucose PET1

Radiology , Volume 223 (2): 453 – May 1, 2002

Loading next page...
 
/lp/radiological-society-of-north-america-inc/t1-lung-cancers-sensitivity-of-diagnosis-with-fluorodeoxyglucose-pet1-h8CnM1Rkme

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Radiological Society of North America, Inc.
Copyright
Copyright © 2002 by Radiological Society of North America
ISSN
1527-1315
eISSN
0033-8419
DOI
10.1148/radiol.2232011131
pmid
11997552
Publisher site
See Article on Publisher Site

Abstract

PURPOSE: To determine the sensitivity of fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with T1 (≤3 cm) lung cancers. MATERIALS AND METHODS: One hundred eighty-five patients with 192 histopathologically proved T1 lung cancers underwent FDG PET imaging at the time of diagnosis. PET results were correlated with tumor size, histopathologic findings, and patient outcome by using the two-sample t test, exact χ 2 test, and log rank test, respectively. RESULTS: Of the 192 lesions, 183 (95%) that ranged in size from 0.5 to 3.0 cm in diameter (mean, 2.0 cm) were positive at PET (ie, demonstrated increased FDG uptake). Of the 192 lesions, nine (5%) that ranged in size from 0.3 to 2.5 cm in diameter (mean, 1.3 cm) were negative at PET (ie, demonstrated low FDG uptake). Patients with small tumors, as well as those with carcinoid tumors and bronchioloalveolar cell carcinoma, were more likely to have a negative PET scan ( P = .004, P = .003, respectively). In addition, patients with a negative PET scan who subsequently proved to have cancer had significantly longer survival than did patients with a positive scan and cancer ( P = .043). CONCLUSION: Most T1 lung cancers show increased FDG uptake on PET scans.

Journal

RadiologyRadiological Society of North America, Inc.

Published: May 1, 2002

There are no references for this article.